Influence of Lengthening the Interval Between Radiochemotherapy and Surgery on Complete Pathological Response in Rectal Cancer (GRECCAR6)
Randomized Control Trial Comparing the Impact of a Lengthening of the Interval Between the Radiochemotherapy and Surgery (7 Weeks vs. 11 Weeks) on Complete Pathological Response in Rectal Cancer
Study Overview
Status
Conditions
Detailed Description
D0: Visit of inclusion and randomization After the end of chemoradiotherapy, the patient is seen in consultation by her / him a surgeon who propose him to participate in the study. At the end of the visit if the patient agrees to participate in it, the investigator at each center will conduct the collection of written consent to the inclusion of the patient. Inclusion will be recorded in the electronic Case Report Form (e-CRF) by the investigator at each center. Randomization (7 or 11 weeks of delay) is performed by the surgeon via the software module CleanWeb randomization.
M1- 1.5 or M2.5 depending of the group randomisation A consultation with the surgeon is held within 15 days (+/- 5 days) of intervention to check the clinical response (tumor regression in rectal tumor distance from the dentate line) and planify surgery. During this visit, the surgeon noted in the e-CRF, clinical findings of the lesion and the results of further investigations.
Not specific exam is requested in the study.
M2 or M3
Surgical procedure:
The anesthesia consultation is planned before the surgery according to the habits of service. Participation in the study does not alter the anesthetic procedures.The patient is admitted the day before surgery in the surgical ward.
During surgery, the operating data are provided on the e-CRF (digital rectal examination under general anesthesia, type of surgery (anterior resection or abdominal-perineal resection), operative time, intraoperative bleeding, macroscopic appearance of the mesorectum, distance from the distal limit of resection). The postoperative complications are noted by the surgeon in the e-CRF during hospitalization (about 10-15 days), and data reporting pathological (Annex 2).
Pathological examination of the specimen of proctectomy is performed according to recommendations for clinical practice using the standard form (Annex 2). The tumor response is evaluated by inclusion of all residual tumor and the response to chemoradiotherapy is graded with the scale of Rödel (Annex 5). A double reading of slides will be made for each patient by two independent pathologists blinded to the randomization group of the patient.
M2 - M5 or M3 - M6 :
Postoperative follow-up :
Following the intervention, no specific consultation is necessary. At follow-up consultations (1 month, 3 months) the surgeon evaluate the postoperative course, planify the stoma closure, noted the potential adverse events and results of morphological examinations (computed tomography, ultrasound, endoscopy) and biological (markers) eventually prescribed.
M6 - M60 :
Cancer surveillance :
Regular follow-up every 3-4 months fo the first two years and every 6 months for the last remaining 3 years (clinical examination, CT-scan and biological marker (CEA))
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75012
- Saint-Antoine Hospital - AP-HP, Department of general and digestive surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age over 18 years, no age limit higher
- Performance status evaluated by the Eastern CooperativeOncology Group (ECOG) score: 0-1,
- Patients with cancer of the middle or lower rectum (lesion located within 10 cm from the dentate line or 12 cm from the anal margin) proved by pathology,
- T3-T4N0, TxN+ on ultrasound-endoscopy and MRI, without secondary localization (M0) on the thoracoabdominal (or chest radiography and abdominal ultrasound)
- Patient who received a protocol between 45-51 Gy of radiotherapy and chemotherapy based on 5-fluorouracil for an average duration of 5 weeks for the management of rectal cancer,
- Curative surgical treatment planned following radiochemotherapy with total mesorectal excision,
- Free and informed consent signed by the patient,
- Patient affiliated to a social security scheme or beneficiary of such plan(except AME)
- Patient able, according to the investigator, to comply with the requirements of the study.
The cessation of chemotherapy during radiotherapy does not exclude the patient from the study.
Exclusion Criteria:
- Patient with metastasis,
- T1 or T2N0 tumor classified by echo-endoscopy and MRI,
- rectal tumor with lower pole is more than 12 cm from the anal margin or 10 cm from the dentate line,
- Patient did not complete the full protocol of radiotherapy,
- History of tumors (other than basal cell carcinoma and / or carcinoma in situ of the cervix) old less than 10 years
- A patient with impaired or incompetent investigator by not allowing him a good understanding of the requirements of the study,
- Person under guardianship, persons under guardianship, persons deprived of their liberty by judicial or administrative body, adult subject to legal protection or unable to consent,
- Patient did not complete the full protocole of chemotherapy,
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 11 weeks
The cancer surgery is practice 11 weeks after neoadjuvant radio-chemotherapy
|
Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.
|
|
Other: 7 weeks
The cancer surgery is practice 7 weeks after neoadjuvant radio-chemotherapy
|
Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of pathological complete response after pathological examination of surgical specimen defined by the absence of persistent tumor cell invasion and lymph node (ypT0N0) in group 7 weeks versus 11 weeks in the group
Time Frame: 6 month
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rates of clinical response to radio-chemotherapy before surgery, comparison between the two groups (7 versus 11 weeks)
Time Frame: 6 month
|
6 month
|
|
|
Rate of tumor regression, comparison between the two groups (7 versus 11 weeks)
Time Frame: 6 month
|
6 month
|
|
|
Rates of operative mortality and morbidity at 90 days, comparison between the two groups (7 versus 11 weeks)
Time Frame: 6 month
|
6 month
|
|
|
Quality of mesorectum resection, comparison between the two groups (7 versus 11 weeks)
Time Frame: 6 month
|
6 month
|
|
|
Rate of sphincter preservation, comparison between the two groups (7 versus 11 weeks)
Time Frame: 6 month
|
6 month
|
|
|
Local and distant recurrence rates, comparison between the two groups (7 versus 11 weeks)
Time Frame: 5 years
|
5 years
|
|
|
Overall survival and disease-free survival rates, comparison between the two groups (7 versus 11 weeks)
Time Frame: 5 years
|
5 years
|
|
|
Functional results (LARS score)
Time Frame: 24 months and 36 months
|
LARS questionnaire (Low Anterior Resection Syndrome questionnaire) completed at 24 months and 36 months
|
24 months and 36 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jérémie Lefèvre, MD, Assistance Publique
Publications and helpful links
General Publications
- Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, Meunier B, Mehrdad J, Cotte E, Desrame J, Karoui M, Benoist S, Kirzin S, Berger A, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech JJ, Meurette G, Lupinacci R, Goasgen N, Parc Y, Simon T, Tiret E. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). J Clin Oncol. 2016 Nov 1;34(31):3773-3780. doi: 10.1200/JCO.2016.67.6049.
- Lefevre JH, Rousseau A, Svrcek M, Parc Y, Simon T, Tiret E; French Research Group of Rectal Cancer Surgery (GRECCAR). A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design. BMC Cancer. 2013 Sep 12;13:417. doi: 10.1186/1471-2407-13-417.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P 110125
- AOM 11304 (Other Identifier: Assistance Publique)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.